Back to CITADEL ADVISORS LLC CITADEL ADVISORS LLC

TCRXTCRX
Showing 8 of 12 quarters

Position history for CITADEL ADVISORS LLCCITADEL ADVISORS LLC's holdings in TSCAN THERAPEUTICS INC

CITADEL ADVISORS LLC holds 1M shares of TCRX (TSCAN THERAPEUTICS INC), worth $989,026 as of 2026-Q2. The position was increased (+216.9% shares). TCRX represents 0.0% of CITADEL ADVISORS LLC's portfolio.

Current Value

$989,026

Current Shares

1M

Total Value Change

+$989,026

Total Shares Change

+1M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
1M
+216.9%
$989,0260.0%$0.98
40
2026-Q1
Increased
318,411
+95.5%
$321,5960.0%$1.03
38
2025-Q4
Decreased
162,877
-58.3%
$162,8770.0%$1.03
0
2025-Q3
Increased
390,747
+78.4%
$711,1600.0%$1.74
37
2025-Q2
Increased
218,987
+302.6%
$317,5320.0%$1.40
38
2025-Q1
Decreased
54,392
-61.9%
$75,0610.0%$1.35
0
2024-Q4
New
142,617
-
$433,5560.0%$3.00
33
2024-Q3
Exited
0
-100.0%
$00.0%$5.04
0

Other major holders of TCRX: ADAGE CAPITAL PARTNERS GP, L.L.C., BlackRock Finance, Inc., BAKER BROS. ADVISORS LP

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used